At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 239 enrolled
Drug / intervention
Nivolumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Cancer. Completed, enrolled 239 participants across 45 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether nivolumab is an effective treatment for cancer that has advanced or has spread. Various tumor types may be eligible for enrollment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesGermany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedJul 2016
Primary CompletionOct 2019
Study CompletionJun 2021
TodayJul 2026
First PostedJul 14, 2016
Enrollment StartFeb 22, 2016
Primary CompletionOct 20, 2019
Study CompletionJun 24, 2021
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 10.0 years ago
Interventions
Nivolumabbiological
Specified dose on specified days